Researchers engineered a cell-penetrating receptor mimic targeting SCARB2 to broadly inhibit EV-A71 and CV-A16, two enteroviruses that can cause severe disease in infants. The work reported improved survival in a lethal neonatal mouse model, suggesting the approach can function in vivo rather than only in cell culture. Because enteroviruses use host entry pathways, receptor-mimic inhibitors can offer a route to block infection early in the lifecycle. The cell-penetrating design is intended to enhance intracellular delivery, where the mimic can engage the relevant entry machinery. Next steps for translation will include dose optimization, safety profiling, and evaluation across additional strains and relevant clinical scenarios.